Focus on fenoldopam: A dopaminergic agonist for severe hypertension

M. A. Munger, E. J. Stanek, Edward A Panacek

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Fenoldopam mesylate is a parenteral post-synaptic dopamine1 receptor agonist currently under FDA review for the treatment of severe hypertension. The agent markedly lowers blood pressure, augments renal blood flow secondary to a reduction in renal vascular resistance, and induces both a diuresis and natriuresis in severe hypertensive patients. Fenoldopam exhibits equivalent blood pressure control and dose-response to nitroprusside. Fenoldopam is relatively well tolerated, devoid of toxic metabolite formation, and requires no protection from light. In consideration of its physiological, clinical, and pharmaceutical advantages, fenoldopam would appear to be a useful addition to the antihypertensive armamentarium.

Original languageEnglish (US)
Pages (from-to)453-460
Number of pages8
JournalHospital Formulary
Volume26
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Fenoldopam
Dopamine Agonists
Hypertension
Blood Pressure
Natriuresis
Neurotransmitter Receptor
Renal Circulation
Poisons
Diuresis
Nitroprusside
Vascular Resistance
Antihypertensive Agents
Kidney
Light
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Focus on fenoldopam : A dopaminergic agonist for severe hypertension. / Munger, M. A.; Stanek, E. J.; Panacek, Edward A.

In: Hospital Formulary, Vol. 26, No. 6, 1991, p. 453-460.

Research output: Contribution to journalArticle

Munger, M. A. ; Stanek, E. J. ; Panacek, Edward A. / Focus on fenoldopam : A dopaminergic agonist for severe hypertension. In: Hospital Formulary. 1991 ; Vol. 26, No. 6. pp. 453-460.
@article{1c7ec1b7c9a84f91b9fdf4bcf5edebf3,
title = "Focus on fenoldopam: A dopaminergic agonist for severe hypertension",
abstract = "Fenoldopam mesylate is a parenteral post-synaptic dopamine1 receptor agonist currently under FDA review for the treatment of severe hypertension. The agent markedly lowers blood pressure, augments renal blood flow secondary to a reduction in renal vascular resistance, and induces both a diuresis and natriuresis in severe hypertensive patients. Fenoldopam exhibits equivalent blood pressure control and dose-response to nitroprusside. Fenoldopam is relatively well tolerated, devoid of toxic metabolite formation, and requires no protection from light. In consideration of its physiological, clinical, and pharmaceutical advantages, fenoldopam would appear to be a useful addition to the antihypertensive armamentarium.",
author = "Munger, {M. A.} and Stanek, {E. J.} and Panacek, {Edward A}",
year = "1991",
language = "English (US)",
volume = "26",
pages = "453--460",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "6",

}

TY - JOUR

T1 - Focus on fenoldopam

T2 - A dopaminergic agonist for severe hypertension

AU - Munger, M. A.

AU - Stanek, E. J.

AU - Panacek, Edward A

PY - 1991

Y1 - 1991

N2 - Fenoldopam mesylate is a parenteral post-synaptic dopamine1 receptor agonist currently under FDA review for the treatment of severe hypertension. The agent markedly lowers blood pressure, augments renal blood flow secondary to a reduction in renal vascular resistance, and induces both a diuresis and natriuresis in severe hypertensive patients. Fenoldopam exhibits equivalent blood pressure control and dose-response to nitroprusside. Fenoldopam is relatively well tolerated, devoid of toxic metabolite formation, and requires no protection from light. In consideration of its physiological, clinical, and pharmaceutical advantages, fenoldopam would appear to be a useful addition to the antihypertensive armamentarium.

AB - Fenoldopam mesylate is a parenteral post-synaptic dopamine1 receptor agonist currently under FDA review for the treatment of severe hypertension. The agent markedly lowers blood pressure, augments renal blood flow secondary to a reduction in renal vascular resistance, and induces both a diuresis and natriuresis in severe hypertensive patients. Fenoldopam exhibits equivalent blood pressure control and dose-response to nitroprusside. Fenoldopam is relatively well tolerated, devoid of toxic metabolite formation, and requires no protection from light. In consideration of its physiological, clinical, and pharmaceutical advantages, fenoldopam would appear to be a useful addition to the antihypertensive armamentarium.

UR - http://www.scopus.com/inward/record.url?scp=0025744762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025744762&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025744762

VL - 26

SP - 453

EP - 460

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 6

ER -